- Home
- RVPHW vs HEPA Comparison
RVPHW vs HEPA Comparison
Compare RVPHW & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- HEPA
- Stock Information
- Founded
- RVPHW N/A
- HEPA 2013
- Country
- RVPHW United States
- HEPA United States
- Employees
- RVPHW 15
- HEPA N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- RVPHW Health Care
- HEPA Health Care
- Exchange
- RVPHW Nasdaq
- HEPA Nasdaq
- Market Cap
- RVPHW N/A
- HEPA N/A
- IPO Year
- RVPHW 2018
- HEPA N/A
- Fundamental
- Price
- RVPHW $0.12
- HEPA $0.75
- Analyst Decision
- RVPHW
- HEPA Hold
- Analyst Count
- RVPHW 0
- HEPA 1
- Target Price
- RVPHW N/A
- HEPA N/A
- AVG Volume (30 Days)
- RVPHW N/A
- HEPA 20.2K
- Earning Date
- RVPHW N/A
- HEPA 11-18-2024
- Dividend Yield
- RVPHW N/A
- HEPA N/A
- EPS Growth
- RVPHW N/A
- HEPA N/A
- EPS
- RVPHW N/A
- HEPA N/A
- Revenue
- RVPHW N/A
- HEPA N/A
- Revenue This Year
- RVPHW N/A
- HEPA N/A
- Revenue Next Year
- RVPHW N/A
- HEPA N/A
- P/E Ratio
- RVPHW N/A
- HEPA N/A
- Revenue Growth
- RVPHW N/A
- HEPA N/A
- 52 Week Low
- RVPHW N/A
- HEPA $0.55
- 52 Week High
- RVPHW N/A
- HEPA $5.30
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- HEPA 61.92
- Support Level
- RVPHW N/A
- HEPA $0.56
- Resistance Level
- RVPHW N/A
- HEPA $0.72
- Average True Range (ATR)
- RVPHW 0.00
- HEPA 0.06
- MACD
- RVPHW 0.00
- HEPA 0.01
- Stochastic Oscillator
- RVPHW 0.00
- HEPA 57.91
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.